Your browser doesn't support javascript.
loading
A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection.
Muir, Andrew J; Arora, Sanjeev; Everson, Gregory; Flisiak, Robert; George, Jacob; Ghalib, Reem; Gordon, Stuart C; Gray, Todd; Greenbloom, Susan; Hassanein, Tarek; Hillson, Jan; Horga, Maria Arantxa; Jacobson, Ira M; Jeffers, Lennox; Kowdley, Kris V; Lawitz, Eric; Lueth, Stefan; Rodriguez-Torres, Maribel; Rustgi, Vinod; Shemanski, Lynn; Shiffman, Mitchell L; Srinivasan, Subasree; Vargas, Hugo E; Vierling, John M; Xu, Dong; Lopez-Talavera, Juan C; Zeuzem, Stefan.
Afiliação
  • Muir AJ; Duke Clinical Research Institute, Duke University, Durham, NC, USA.
  • Arora S; University of New Mexico, Albuquerque, NM, USA.
  • Everson G; University of Colorado Denver & Hospital, Aurora, CO, USA.
  • Flisiak R; Medical University of Bialystok, Bialystok, Poland.
  • George J; Westmead Hospital, Westmead Millennium Institute and University of Sydney, Westmead, NSW, Australia.
  • Ghalib R; Texas Clinical Research Institute, Arlington, TX, USA.
  • Gordon SC; Henry Ford Hospital, Detroit, MI, USA.
  • Gray T; ZymoGenetics, Bristol-Myers Squibb, Seattle, WA, USA.
  • Greenbloom S; Toronto Digestive Disease Associates, Inc., Vaughan, ON, Canada.
  • Hassanein T; SCTI Research Foundation, Coronado, CA, USA.
  • Hillson J; ZymoGenetics, Bristol-Myers Squibb, Seattle, WA, USA.
  • Horga MA; Research and Development, Bristol-Myers Squibb, Wallingford, CT, USA.
  • Jacobson IM; Weill Cornell Medical College, New York, NY, USA.
  • Jeffers L; Miami VA Medical Center, Miami, FL, USA.
  • Kowdley KV; Virginia Mason Medical Center, Seattle, WA, USA.
  • Lawitz E; The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA.
  • Lueth S; Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
  • Rodriguez-Torres M; Fundación de Investigación, San Juan, Puerto Rico.
  • Rustgi V; Metropolitan Research, Fairfax, VA, USA.
  • Shemanski L; ZymoGenetics, Bristol-Myers Squibb, Seattle, WA, USA.
  • Shiffman ML; Liver Institute of Virginia, Newport News/Richmond, VA, USA.
  • Srinivasan S; Research and Development, Bristol-Myers Squibb, Wallingford, CT, USA. Electronic address: subasree.srinivasan@bms.com.
  • Vargas HE; Mayo Clinic in Arizona, Phoenix, AZ, USA.
  • Vierling JM; Advanced Liver Therapies at St. Luke's Episcopal Hospital, Baylor College of Medicine, Houston, TX, USA.
  • Xu D; Research and Development, Bristol-Myers Squibb, Wallingford, CT, USA.
  • Lopez-Talavera JC; Research and Development, Bristol-Myers Squibb, Wallingford, CT, USA.
  • Zeuzem S; Department of Medicine, JW Goethe University Hospital, Frankfurt, Germany.
J Hepatol ; 61(6): 1238-46, 2014 Dec.
Article em En | MEDLINE | ID: mdl-25064437
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Interferons / Hepacivirus / Hepatite C Crônica Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Interferons / Hepacivirus / Hepatite C Crônica Idioma: En Ano de publicação: 2014 Tipo de documento: Article